Fate Therapeutics (F6T) AI Stock Analysis

Fate Therapeutics

(Frankfurt:F6T)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Proprietary cell-therapy platformFate’s proprietary iPSC, cell-engineering, and manufacturing capabilities provide a platform for developing multiple allogeneic immune-cell products. An off-the-shelf approach could support broader treatment access and more scalable deployment than highly individualized cell therapies if clinical development succeeds.

Negative Factors

No commercial product revenueWithout an approved therapy generating recurring product sales, Fate lacks a proven commercial revenue base to support ongoing operations. Collaboration and licensing income can be uneven and milestone-dependent, leaving future funding and business progress closely tied to development outcomes and partner activity.

Fate Therapeutics (F6T) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 234.28M
Dividend Yield: ―
Average Volume (3M): 665
Price to Earnings (P/E): -1.9
Beta (1Y): 1.58
Revenue Growth: -28.37%
EPS Growth: 32.58%
Country: Germany
Employees: 161
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Fate Therapeutics Business Overview & Revenue Model

Company Description

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A signifi...

Fate Therapeutics Earnings Call Summary

Earnings Call Date:May 08, 2024(Q1-2024)|% Change Since:-46.45%|Next Earnings Date:Oct 28, 2026

Earnings Call SentimentNeutral

The earnings call highlighted significant progress in clinical trials, particularly with FT819 and FT522, alongside a strong financial position. However, revenue growth remains limited and operating expenses are high, suggesting a balanced outlook with promising clinical achievements countered by financial challenges.

Positive Updates

FT819 and FT522 Data Presentation

Presented promising data from FT819 and FT522 programs at the ASGCT Annual Meeting, showing potential disease-modifying effects and immune reset in B-cell-mediated autoimmune diseases.

Negative Updates

Limited Revenue Growth

Reported revenue of $1.9 million, consistent with prior quarters, reflecting limited growth.

Company Guidance

During the Fate Therapeutics Q1 2024 earnings call, the company provided guidance on its clinical and financial outlook. Key program initiatives were discussed, including the FT819 CAR T-cell and FT522 CAR NK cell programs, with notable translational data presented at the American Society of Gene and Cell Therapy Annual Meeting. The company highlighted its plans to achieve several clinical milestones across its iPSC product pipeline, targeting both cancer and autoimmune diseases. Financially, Fate Therapeutics raised $100 million through an underwritten offering and private placement, ending the first quarter with approximately $391 million in cash. Operating expenses for the full year are projected between $215 million and $230 million, with a year-end cash balance exceeding $270 million. The company's strategic focus is on demonstrating the disease-modifying potential of its therapies while maintaining a strong financial position to support ongoing and future clinical development.

Fate Therapeutics Risk Analysis

Fate Therapeutics disclosed 90 risk factors in its most recent earnings report. Fate Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.Off-label use or misuse of any product candidates we may get approved in the future may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.Q2, 2026

Fate Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:F6T against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CGEN	65Neutral	$187.56M	5.27	42.57%	―	234.18%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONCY	45Neutral	$54.24M	-1.63	1020.21%	―	―	2.05%
STTK	45Neutral	$558.02M	-10.43	-43.57%	―	-66.63%	57.89%
CRDF	43Neutral	$69.21M	-1.41	-103.08%	―	-6.96%	32.77%
NKTX	39Underperform	$111.73M	-0.97	-39.64%	―	―	-6.70%

* Healthcare Sector Average

Performance Comparison

DE:F6T and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:F6T	Fate Therapeutics Inc	1.83	0.70	62.12%
CGEN	Compugen	1.98	0.37	22.98%
ONCY	Oncolytics Biotech	0.40	-0.56	-58.51%
CRDF	Cardiff Oncology, Inc.	0.84	-1.38	-61.98%
NKTX	Nkarta, Inc.	1.52	-0.45	-22.84%
STTK	Shattuck Labs, Inc.	5.32	3.39	175.65%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Fate Therapeutics AI Stock Analysis